The House Oversight Committee will hold two days of hearings this week with six drug industry CEOs. The hearings are the presumptive climax of an 18-month investigation first launched by the late Rep. Elijah Cummings in 2019.
The hearing could be the most perilous yet for drug makers, who have managed to avoid any major missteps at the multiple congressional drug pricing hearings that preceded this one. The committee’s probe was extensive: Staff reviewed more than a million pages of internal documents from drug companies. And while we don’t know yet what the committee plans to reveal during the hearings, which are scheduled for Wednesday and Thursday, many of the drugs at the center of the probe already have a long and sordid history when it comes to pricing.
Below, STAT walks through six of the major drugs that the committee included in its probe: